Gennao Bio Presents Promising New Results from its Gene Monoclonal Antibody (GMAB) Platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting
- Preclinical studies demonstrated ability of GMAB platform to systemically target and deliver RIG-I ligand 3p-hpRNA to multiple difficult-to-treat tumor models and suppress tumor growth - - Studies of GMAB/3p-hpRNA ...